Dr. Lal Path Labs
LALPATHLAB · NSEValuation
Blended fair value using DCF and peer comparison methods.
Peer comparison
How this company stacks up against sector peers on valuation and quality metrics.
Healthcare · 8 peers · sector medians shown
| Company | Mkt Cap | P/E | P/B | EV/EBITDA | ROE | Net Margin | Rev CAGR 3y |
|---|---|---|---|---|---|---|---|
Dr. Lal Path Labs LALPATHLAB · you | ₹27,012 Cr | 53.4× | 10.7× | 35.9× | 20.1% | 18.3% | 11.1% |
| Sector median | — | 64.5× | 8.8× | 37.4× | 13.7% | 12.0% | 18.4% |
| Apollo Hospitals APOLLOHOSP | ₹1.2 L Cr | 61.1× | 12.5× | — | 20.5% | 7.7% | 14.9% |
| Max Healthcare Institute MAXHEALTH | ₹97,655 Cr | 68.0× | 9.1× | 45.6× | 13.4% | 17.2% | 22.4% |
| Fortis Healthcare FORTIS | ₹74,835 Cr | 71.7× | 7.5× | 37.4× | 10.5% | 11.4% | 13.2% |
| Aster DM Healthcare ASTERDM | ₹40,777 Cr | 105.1× | 8.9× | 47.6× | 8.5% | 8.4% | 15.7% |
| Narayana Hrudayalaya NH | ₹39,489 Cr | 47.9× | 8.6× | 28.2× | 17.8% | 10.2% | 20.4% |
| Global Health MEDANTA | ₹33,396 Cr | 60.1× | 8.4× | 37.0× | 14.0% | 12.6% | 17.9% |
| Poly Medicure POLYMED | ₹14,772 Cr | 46.0× | 4.8× | 34.0× | 10.4% | 17.2% | 18.9% |
| Vijaya Diagnostic Centre VIJAYA | ₹13,346 Cr | 77.9× | 14.1× | 39.6× | 18.1% | 21.2% | 21.0% |
Dr. looks attractively valued — trading at a discount to sector peers on P/E (53.4× vs sector median 64.5×) while delivering above-average returns on equity (20.1% vs 13.7%).
Business quality
Key profitability, efficiency, and solvency metrics.
Financial health
Piotroski F-Score, Altman Z-Score, and key solvency ratios.
Full financial data
Charts and annual statements for income, balance sheet and cash flow.
Income trend
Revenue, profit and margin trends over time.
Cash flow
Where cash comes from and where it goes.
Balance sheet
Assets show what the company owns. Liabilities show what it owes. Equity is what's left for shareholders.
How the company is funded — equity is owners' money, debt is long-term borrowing, current liabilities are short-term obligations.